Publication of List of Manufacturer Granted Licence for the Manufacture of Therapeutic Goods - Boehringer Ingelheim Pty Ltd

Overview

The Therapeutic Goods Act 1989, enacted by the Parliament of Australia, aims to regulate the supply of therapeutic goods within the country, ensuring that such goods are safe, of high quality, and effective. The Act addresses the need for a comprehensive regulatory framework governing the manufacture, importation, and distribution of therapeutic goods, including medicines, medical devices, and blood products. By establishing a licensing system, the Act seeks to uphold public health and safety by granting licences only to manufacturers who meet stringent quality and safety standards. This legislative measure ensures that therapeutic goods available to the Australian public are reliable and meet necessary health regulations, thus safeguarding consumer interests and promoting effective healthcare practices. The Therapeutic Goods Administration, a division of the Department of Health, is responsible for the administration and enforcement of the Therapeutic Goods Act 1989. The publication of the list of manufacturers granted a licence to manufacture therapeutic goods, such as the recent licence granted to Boehringer Ingelheim Pty Ltd, is a direct application of Section 38 of the Act. This publication serves to inform the public and stakeholders about the entities authorised to produce therapeutic goods, thereby maintaining transparency and accountability in the therapeutic goods supply chain.

Scope and Application

The Therapeutic Goods Act 1989 applies to entities involved in the manufacturing, importation, supply, advertising, and sponsorship of therapeutic goods in Australia. This Act establishes a framework for the regulation of therapeutic goods, ensuring that these products are safe, of high quality, and meet efficacy standards. Specifically, the Act applies to companies and individuals who engage in any of these activities related to therapeutic goods, which include medicines, medical devices, blood, and tissues. The geographic reach of the Act is national, encompassing the entire Commonwealth of Australia, and it applies to all states and territories. However, certain goods may be exempt from the licensing requirements under specific conditions, such as low-risk medical devices or small quantities of certain substances used for research purposes. The application and scope of the Act can be extended or restricted through subordinate instruments, which provide detailed regulations and guidelines for compliance. For instance, the Act may specify particular classes of goods that are subject to stricter controls or outline the procedural requirements for obtaining a manufacturing licence. The publication of the list of manufacturers granted a licence, such as the one for Boehringer Ingelheim Pty Ltd, serves to inform the public and regulatory bodies of entities authorised to manufacture therapeutic goods within the Australian jurisdiction.

Key Provisions

The Therapeutic Goods Act 1989, under Section 38, allows the Secretary to grant a licence to a party for the manufacture of therapeutic goods. The gazetted notice specifies that this licence has been granted to Boehringer Ingelheim Pty Ltd, with the licence number mi-2013-li-06919-1, for their premises at level 1, 78 Waterloo Road, North Ryde, NSW, 2113. This licence is essential for Boehringer Ingelheim to legally manufacture therapeutic goods within Australia. The licence grants them the authority to produce therapeutic goods, subject to compliance with all relevant regulatory requirements and quality standards set forth by the Therapeutic Goods Administration. The obligations imposed by the Therapeutic Goods Act on the licensee, Boehringer Ingelheim, include adhering to strict manufacturing standards and regulatory compliance. They must ensure that their manufacturing processes meet the quality and safety standards stipulated by the Therapeutic Goods Administration. This involves maintaining proper documentation, implementing quality control measures, and undergoing regular inspections to verify compliance. Furthermore, Boehringer Ingelheim is required to report any adverse events related to their products and to maintain records of their manufacturing activities. Failure to meet these obligations can result in the suspension or revocation of their manufacturing licence. Breaches of the Therapeutic Goods Act can lead to significant legal consequences. If Boehringer Ingelheim fails to comply with the requirements of their manufacturing licence or breaches any provisions of the Act, they may face enforcement actions. This can include fines, the imposition of corrective measures, or even the suspension or revocation of their manufacturing licence. Under Section 42AB of the Therapeutic Goods Act 1989, an individual can be fined up to $1,215,000, while a body corporate can be fined up to $6,075,000 for serious or repeated breaches. These penalties reflect the seriousness with which the Act treats non-compliance and the importance of maintaining high standards in the manufacture of therapeutic goods.